KRAS is justifiably renowned as one of the most highly mutated oncogenes in human cancers and implicated in poor survival, particularly in pancreatic (~95%), colorectal (~41%), and lung (~32%) cancers1,2. This evidence concerns the gene KRAS and cancer.